Print
29 January 2018
GMP News
The award of the Government of the Russian Federation in the area of science and technology was given for the development, manufacturing and implementation of Russian radioactive sources for contact radiation therapy in oncology.
Russian scientists, doctors, and engineers have developed radioactive sources based on iodine-125, cobalt-60 and iridium-192 for contact radiation therapy. Currently, Russia has the technology for manufacturing these sources and started their industrial production.
The import-substituting manufacturing of radioactive sources served as the basis to develop the medical technologies for low-dose and high-dose contact radiation therapy, including interstitial, intracavitary and applicator-guided radiation therapy. The developed medical technologies that allow to use the manufactured sources for contact radiotherapy were implemented in medical institutions of 13 subjects of the Russian Federation and 2 CIS countries. The implementation of this medical technologies improved the efficacy of treatment, ensured early medical and social rehabilitation and high quality of life for oncology patients. It also allowed to achieve high economic efficiency. So far, the invention has no analogs in the world.
R&D and industrial deployment of technology were implemented by the Federal State Budgetary Institution National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Federal State Budgetary Institution Russian Scientific Center of Radiology of the Ministry of Health of the Russian Federation, State Scientific Center of the Russian Federation I.I. Leypunsky Institute of Physics and Power Engineering, Scientific Research Institute of Technical Physics and Automation Joint-Stock Company of Rosatom Corporation.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.